Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhouyu Ning

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5103916711. Sources: OpenAlex.

Their work

Papers
21 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2016: 4 papers · 2017: 1 paper · 2018: none · 2019: 5 papers · 2020: 1 paper · 2021: 5 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 21

  1. A multi-stage prospective study evaluates serum metabolomic signatures for the differential diagnosis and prognostic stratification of PDAC. Co-author DOI 10.1016/j.tranon.2026.103025↗
  2. Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal aden… Co-author DOI 10.1038/s41392-024-02052-3↗
  3. Exploring the efficacy and safety of drug-eluting beads transarterial chemoembolization in pancreatic cancer liver metastasis. Co-author DOI 10.1093/bjr/tqae059↗
  4. Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34334↗
  5. Case Report: Overcoming challenges in pancreatic cancer with liver metastases: a personalized therapeutic odyssey of TACE, ablation, and immunotherapy. First author DOI 10.3389/fimmu.2023.1275782↗
  6. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Co-author DOI 10.1016/j.lfs.2021.119205↗
  7. Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Co-author DOI 10.1016/j.omtn.2021.06.015↗
  8. Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study. First author DOI 10.1080/17474124.2021.1869937↗
  9. CMTM8 as an LPA1-associated partner mediates lysophosphatidic acid-induced pancreatic cancer metastasis. Co-author DOI 10.21037/atm-20-1013↗
  10. NUCB1 Suppresses Growth and Shows Additive Effects With Gemcitabine in Pancreatic Ductal Adenocarcinoma via the Unfolded Protein Response. Co-author DOI 10.3389/fcell.2021.641836↗
  11. USP51, an oncogene for pancreatic cancer (PC) cell growth via Wnt/β-catenin pathway Co-author DOI 10.21203/rs.3.rs-20243/v1↗
  12. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Co-author DOI 10.1093/carcin/bgz067↗
  13. Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression. Co-author DOI 10.1186/s13046-019-1055-9↗
  14. Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upreg… Co-author DOI 10.18632/aging.102307↗
  15. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Co-author DOI 10.2147/ott.s185424↗
  16. High-intensity focused ultrasound enhances the effect of bufalin by inducing apoptosis in pancreatic cancer cells. Co-author DOI 10.2147/ott.s185953↗
  17. Low serum miR-373 predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.3233/cbm-170231↗
  18. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter coh… First author DOI 10.18632/oncotarget.13000↗
  19. Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling. First author DOI 10.3892/mmr.2016.5471↗
  20. A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer. Co-author PMID 27448780↗
  21. Radiation promotes epithelial-to-mesenchymal transition and invasion of pancreatic cancer cell by activating carcinoma-associated fibroblasts. Co-author PMID 27822411↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiqiang Meng · 13 shared papers, 2016–2024 · strength 1.55
  2. Yongqiang Hua · 9 shared papers, 2016–2024 · strength 1.11
  3. Zhiqiang Meng · 4 shared papers, 2020–2026 · strength 0.92
  4. Weidong Shi · 6 shared papers, 2016–2021 · strength 0.62
  5. Liping Zhuang · 5 shared papers, 2016–2023 · strength 0.53
  6. Yan Xia · 3 shared papers, 2019–2024 · strength 0.48
  7. Chenyue Zhang · 5 shared papers, 2016–2021 · strength 0.47
  8. Ying Zhu · 1 shared paper, 2026 · strength 0.43
  9. Zhen Chen · 5 shared papers, 2016–2021 · strength 0.43
  10. Luming Liu · 4 shared papers, 2017–2021 · strength 0.42
  11. Ke Zhang · 3 shared papers, 2019–2021 · strength 0.39
  12. Luming Liu · 4 shared papers, 2016–2021 · strength 0.38
  13. Lianyu Chen · 4 shared papers, 2016–2021 · strength 0.33
  14. Zhu Ying · 1 shared paper, 2023 · strength 0.31
  15. Xiaoyan Zhu · 3 shared papers, 2016–2024 · strength 0.30
  16. Yehua Shen · 3 shared papers, 2016–2021 · strength 0.27
  17. Peng Wang · 2 shared papers, 2017–2023 · strength 0.26
  18. Chien‐shan Cheng · 2 shared papers, 2016–2023 · strength 0.25
  19. Luming Liu · 2 shared papers, 2020–2021 · strength 0.24
  20. Jing Xie · 2 shared papers, 2016–2024 · strength 0.22
  21. Hao Chen · 3 shared papers, 2016–2019 · strength 0.20
  22. Changjing Huang · 1 shared paper, 2023 · strength 0.19
  23. Wen‐Bin Zou · 1 shared paper, 2023 · strength 0.19
  24. Lixia Yi · 1 shared paper, 2024 · strength 0.18
  25. Waimei Si · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.